Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869764 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
A Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01869764: Completed Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by Wake Forest University Health Sciences.
NCT01869764 is a Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 57 participants, below the 317-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01869764, a Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.
Primary Outcome
Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG omega-3 fatty acid
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
What the finished NCT01869764 record still lists
NCT01869764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 317-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (82% lower).
The record links to 9 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01869764 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01869764 about?
NCT01869764 is a clinical study titled "Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer". This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty a...
What is the current status of trial NCT01869764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2013-11. Estimated completion is 2018-07.
What conditions does trial NCT01869764 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Male Breast Cancer.
What interventions are being tested in trial NCT01869764?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), omega-3 fatty acid (DRUG).
Who is sponsoring clinical trial NCT01869764?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01869764 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01869764's enrollment target sits among peer trials
57 21st of 30 higher than 10 of 30 other Stage II Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
MARGetuximab Or Trastuzumab (MARGOT)
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
ACTIVE NOT RECRUITING · Phase 2
-
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
ACTIVE NOT RECRUITING · Phase 2
-
Acupuncture Pilot Study for Cancer-related Cognitive Function
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia